ArticlemedRxiv : the preprint server for health sciences2026
Effects of Genetically-Proxied Antihypertensive Drug Targets on Preeclampsia and Birth Weight.
Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality, and a major contributor to low birth weight. Beta blockers (BB) and calcium channel blockers (CCB) are the most commonly recommended agents to treat hypertension in pregnancy. Yet it remains unknown whether these agents alter the risk of preeclampsia (PE), and if so, whether effects arise through maternal physiology or through direct fetal mechanisms. Objectives: To use drug-target Mendelian randomization (MR) to estimate the effects of genetically-proxied inhibition of beta-adrenergic and L-type calcium-channel targets on PE risk, birth weight, partitioned into maternal and fetal genetic components, and gestational age (GA). Methods: We constructed instruments from genome-wide significant, LD-independent variants within prespecified windows around systolic blood pressure (SBP) modulating drug targets in addition to a genome-wide SBP instrument (European ancestry). Outcomes comprised of PE (16,349 cases / 595,135 controls), maternal and fetal genetic effects on birth weight (n≈210,267 and n≈298,142), and GA (n≈151,987). Two-sample MR estimated effects per 5mmHg decrease in SBP. Bayesian colocalization assessed shared causal variants. Multiple testing was controlled with Benjamini-Hochberg correction. Results: Genetically lower SBP was associated with reduced PE risk and modest increases in birth weight and GA. BB (ADRB1) target inhibition showed no convincing reduction in PE risk but was associated with lower birth weight, with associations predominantly through direct fetal genetic effects and strong colocalization at ADRB1 with fetal birth-weight signals. In contrast, CCB targets collectively associated with lower PE risk without consistent evidence of fetal growth impairment; colocalization support for individual CCB loci was limited. Sensitivity analyses (heterogeneity, pleiotropy) did not materially alter these patterns where instrument counts permitted. Conclusions: Drug-target MR suggests that BB pathways are unlikely to meaningfully reduce PE and are linked to reduced fetal growth - chiefly via direct fetal mechanisms. In contrast, CCB pathways are associated with lower PE risk and largely neutral fetal growth effects. These findings support prioritizing CCBs for evaluation in comparative trials of PE prevention.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.